[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573918":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":35,"collaborators":25,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":25,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":25,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":59,"whyStopped":25,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":25},{"fullName":5,"class":6},"Assiut University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","EXPERIMENTAL","patients will receive SPGB block with 2 ml volume on each side (1.5 mL of bupivacaine 0.5% + 0.5 mL of magnesium sulphate 10%)",[13,14],"Drug: Bupivacaine","Drug: Magnesium Sulphate 500 mg",{"label":16,"type":10,"description":17,"interventionNames":18},"group B","patients will receive SPGB block with 2 ml volume on each side (1.5 ml bupivacaine 0.5% plus 0.5 ml saline).",[13],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Bupivacaine","patients will receive SPGB block with 2 ml volume on each side (1.5 mL of bupivacaine 0.5% + 0.5 mL of magnesium sulphate 10%).",[9,16],null,{"type":21,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Magnesium Sulphate 500 mg",[9],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Ahmed Mohamed Ali Ismaeil, resident doctor","CONTACT","+20106 9071633","Ahmed.16285222@med.aun.edu.eg",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Ahmed Mohamed Ali Ismaeil","resident doctor at Assiut University hospital","100573918","phase-4-opioid-sparing-effect-of-sphenopalatine-ganglion-block-in-functional-endoscopic-sinus-surgery-a-randomized-controlled-clinical-trial-100573918",false,"NCT06752525","Opioid Sparing Effect of Sphenopalatine Ganglion Block in Functional Endoscopic Sinus Surgery: a Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n* • Patients programmed for elective FESS\n\n  * American society of anaesthesiologists (ASA) physical state I-II\n  * Age over 18 years and less than 60-years-old.\n\nExclusion Criteria:\n\n* • Known hypersensitivity to the study drugs.\n\n  * Inability to accurately describe postoperative pain to investigators.\n  * Opioid tolerance or dependence.\n  * Patient refusal\n  * History of renal, liver, cardiac, neuropsychiatric disorder problems.\n  * Bleeding or coagulation abnormality.\n  * Infection at the site of injection","ALL","18 Years","60 Years",{"count":49,"type":50},60,"ESTIMATED","INTERVENTIONAL",[53],"PHASE4","Functional endoscopic sinus surgery (FESS) is widely recognized as a safe and preferred treatment option for various conditions, particularly nasal polyps and rhinosinusitis . This technique has been shown to improve postoperative symptoms by 86.3% in patients with chronic inflammatory paranasal sinus diseases .\n\nThe aim of this study is to evaluate the effect of adding of MgSO4 to bupivacaine via SPGB block for postoperative pain for 24 hours in patients scheduled for FESS as opioid free anaesthesia.",[56],"Sinus Surgery",[58],"sphenopalatine ganglion block","NOT_YET_RECRUITING","2024-12-22",{"date":62,"type":63},"2024-12-30","ACTUAL",{"date":65,"type":50},"2025-01-01",{"date":67,"type":50},"2026-03-01",{"name":5,"class":6}]